Liposarcoma is a rare form of cancer that develops in the soft tissues of the body. Specifically, it originates in fat cells and can occur in various parts of the body, including the limbs, abdomen, and retroperitoneum (the area behind the abdominal cavity). It primarily affects soft tissues, such as the muscles, deep tissues of the thigh or abdomen, and retroperitoneum. Liposarcoma is a rare type of cancer that develops in fat cells. It typically occurs in the soft tissues of the limbs or abdomen. While treatment for liposarcoma depends on various factors such as tumor size, location, and stage, there are several effective treatment options available.
Types
This malignant tumor can occur in various parts of the body and is classified into different types based on its characteristics and location and the types of liposarcoma,
- Well-Differentiated Liposarcoma: Well-differentiated liposarcoma is the most common type of liposarcoma, accounting for approximately 50% of all cases. It typically occurs in deep soft tissues, such as the thigh, retroperitoneum, or abdominal cavity. This type of liposarcoma grows slowly and often presents as a painless, slowly enlarging mass. Although it rarely spreads to other parts of the body, it has a high tendency for local recurrence.
- Myxoid Liposarcoma: Myxoid liposarcoma is the second most common type, accounting for around 30% of liposarcoma cases. It commonly affects the extremities, particularly the thigh and buttock region. Myxoid liposarcoma is characterized by a gelatinous or mucinous appearance and has a higher tendency to spread to other parts of the body compared to well-differentiated liposarcoma. Symptoms may include pain, swelling, and a palpable mass.
- Dedifferentiated Liposarcoma: Dedifferentiated liposarcoma is a more aggressive subtype, accounting for approximately 10-15% of liposarcoma cases. It often arises from pre-existing well-differentiated or myxoid liposarcomas. This type tends to grow rapidly, invade nearby tissues, and has an increased risk of metastasis (spreading) to other organs. Symptoms may include pain, limited mobility, and the presence of a large, firm mass.
- Pleomorphic Liposarcoma: Pleomorphic liposarcoma is a rare and aggressive variant of liposarcoma. It accounts for less than 5% of all liposarcoma cases. Pleomorphic liposarcoma can occur in any age group and commonly affects the limbs. It is characterized by the presence of pleomorphic cells, which are irregularly shaped and vary in size. Symptoms may include pain, swelling, and a rapidly growing mass.
- Mixed-Type Liposarcoma: Mixed-type liposarcoma refers to a liposarcoma that contains components of different subtypes, such as well-differentiated and dedifferentiated liposarcoma. This type is less common and presents with a combination of features seen in the respective subtypes. Treatment approaches for mixed-type liposarcoma depend on the predominant component and its characteristics.
Causes
Understanding the causes of liposarcoma can help raise awareness, promote early detection, and encourage proactive measures and potential causes of liposarcoma, providing detailed information in simple English.
- Genetic Predisposition: Some individuals may have a genetic predisposition to developing liposarcoma, as certain genetic mutations can increase the risk.
- Aging: Advancing age is a significant risk factor for liposarcoma, with the majority of cases occurring in individuals over the age of 40.
- Hereditary Factors: In rare cases, liposarcoma can be hereditary, meaning it runs in families due to specific genetic abnormalities passed down through generations.
- Radiation Exposure: Exposure to high levels of radiation, such as during cancer treatments or in certain occupational settings, may increase the likelihood of developing liposarcoma.
- Chemotherapy: Previous chemotherapy treatments, especially those involving certain drugs, can elevate the risk of developing liposarcoma.
- Trauma: Severe and repeated trauma or injury to an area of the body might trigger liposarcoma formation, although the exact mechanisms are still under investigation.
- Pre-existing Lipoma: Lipoma, a non-cancerous fatty tumor, can undergo malignant transformation into liposarcoma in rare cases.
- Inflammation: Chronic inflammation, resulting from conditions like long-standing infections or autoimmune diseases, might contribute to the development of liposarcoma.
- Obesity: While not directly causing liposarcoma, obesity is associated with an increased risk due to the higher number of fat cells present in the body.
- Hormonal Imbalances: Fluctuations or imbalances in hormones, such as estrogen, might play a role in the development of liposarcoma, although further research is needed.
- Exposure to Environmental Toxins: Certain environmental toxins, such as industrial chemicals or pollutants, may contribute to the development of liposarcoma, although the specific links are not yet fully understood.
- Family History: Having a family history of liposarcoma or other soft tissue sarcomas may increase an individual’s risk of developing the disease.
- Li-Fraumeni Syndrome: People with Li-Fraumeni syndrome, a rare genetic disorder, have an increased susceptibility to multiple types of cancer, including liposarcoma.
- Paget’s Disease: Paget’s disease of the bone, a condition characterized by abnormal bone remodeling, has been associated with an elevated risk of developing liposarcoma.
- Immunodeficiency: Individuals with weakened immune systems, such as those with HIV/AIDS or those undergoing organ transplantation, may have a higher likelihood of developing liposarcoma.
- Human Herpesvirus 8 (HHV-8) Infection: HHV-8 infection, known to cause Kaposi sarcoma, has also been linked to the development of liposarcoma in rare instances.
- Neurofibromatosis Type 1 (NF1): NF1, a genetic disorder characterized by the formation of tumors along nerves, can increase the risk of developing liposarcoma.
- Gardner Syndrome: Individuals with Gardner syndrome, an inherited disorder characterized by the growth of polyps in the colon, may have an increased risk of liposarcoma.
- Multiple Endocrine Neoplasia Type 1 (MEN1): MEN1, a rare genetic syndrome involving tumors in multiple endocrine glands, has been associated with an elevated risk of liposarcoma.
- Retinoblastoma: Patients with a history of retinoblastoma, a rare eye cancer in children, may have an increased risk of developing liposarcoma later in life.
- Neurofibromatosis Type 2 (NF2): NF2, another genetic disorder characterized by the growth of tumors, particularly in the nervous system, has been linked to liposarcoma development.
- Lymphedema: Chronic lymphedema, a condition characterized by fluid retention and swelling, may increase the risk of developing liposarcoma in affected areas.
- Hormone Replacement Therapy (HRT): Long-term use of hormone replacement therapy, particularly estrogen-only regimens, has been associated with a slight increase in the risk of developing liposarcoma.
- Chemical Exposure: Exposure to certain chemicals, such as vinyl chloride or dioxins, used in industrial processes, may contribute to the development of liposarcoma.
- Alcohol Consumption: Excessive and prolonged alcohol consumption may weaken the immune system and potentially increase the risk of liposarcoma development.
- Smoking: While the direct link is not well-established, smoking has been associated with an increased risk of various types of cancer, including liposarcoma.
- Diabetes: Although the exact connection is unclear, some studies suggest that individuals with diabetes may have a slightly elevated risk of developing liposarcoma.
- Use of Anabolic Steroids: Long-term use of anabolic steroids has been suggested to increase the risk of developing liposarcoma, although more research is needed to establish a definitive link.
- Viral Infections: Certain viral infections, such as human papillomavirus (HPV) or Epstein-Barr virus (EBV), have been implicated in the development of liposarcoma, but their role is still being studied.
- Unknown Factors: In some cases, the cause of liposarcoma remains unknown, highlighting the need for further research to identify potential underlying factors.
Symptoms
Symptoms associated with liposarcoma, their significance, and why it’s important to seek medical attention if you experience any of these signs.
- Persistent Pain: One of the most common symptoms of liposarcoma is persistent pain in the affected area. The pain may worsen over time and is often accompanied by swelling.
- Palpable Mass: A palpable mass or lump in the soft tissues is another typical symptom. The mass may be soft or firm to the touch and may increase in size over time.
- Swelling: Swelling around the affected area can occur due to the growing tumor. It may cause discomfort and restrict movement.
- Limited Range of Motion: Liposarcoma near joints or muscles can impair the range of motion. If you experience difficulty in moving a limb or joint, it could be a symptom worth investigating.
- Fatigue: Unexplained fatigue or a general feeling of tiredness may be present in individuals with liposarcoma. The underlying cancer can sap energy levels and impact overall well-being.
- Weight Loss: Sudden and unexplained weight loss may occur due to the metabolic demands of the growing tumor or the body’s response to cancer.
- Abdominal Discomfort: Liposarcomas in the abdomen can cause discomfort, pain, or a sense of fullness due to the pressure exerted on nearby organs.
- Nausea and Vomiting: When liposarcomas develop near the stomach or intestines, they can interfere with normal digestion, leading to nausea and vomiting.
- Changes in Bowel Habits: If the liposarcoma affects the intestines, it may result in changes in bowel habits, such as constipation or diarrhea.
- Hematuria: Liposarcoma near the kidneys or bladder may cause blood in the urine, known as hematuria. This symptom requires immediate medical attention.
- Frequent Urination: A liposarcoma pressing against the bladder can lead to increased frequency of urination. If it’s not related to a known urinary condition, it should be evaluated.
- Chest Pain and Cough: In rare cases where liposarcomas affect the lungs or chest wall, symptoms such as chest pain, persistent cough, or shortness of breath may occur.
- Difficulty Swallowing: Liposarcomas located in the throat or esophagus can cause difficulty in swallowing (dysphagia) and discomfort while eating.
- Hoarseness: When a liposarcoma affects the vocal cords or nearby structures, it can lead to hoarseness or changes in the voice quality.
- Headaches and Vision Problems: Liposarcomas in the head or neck region may present with symptoms such as headaches, vision problems, or hearing loss.
- Bone Pain: In rare cases, liposarcomas can spread to the bones, causing localized bone pain and increasing the risk of fractures.
- Neurological Symptoms: Liposarcomas that affect the nerves can cause neurological symptoms like weakness, numbness, or tingling in the affected area.
- Abnormal Bleeding: If a liposarcoma is located near blood vessels or affects the circulatory system, it may lead to abnormal bleeding or easy bruising.
- Anemia: In some cases, liposarcoma can cause anemia due to chronic bleeding or the body’s decreased ability to produce red blood cells.
- Enlarged Lymph Nodes: Advanced liposarcoma may spread to the nearby lymph nodes, resulting in their enlargement and tenderness.
Diagnosis
Timely and accurate diagnosis of liposarcoma is crucial for effective treatment and management a comprehensive list of essential diagnoses and tests for liposarcoma, ensures a thorough understanding of the diagnostic process. Read on to learn more about these procedures and their significance in identifying liposarcoma.
- Physical Examination: During a physical examination, a healthcare professional assesses the affected area, looking for any noticeable lumps, swelling, or abnormalities. This initial evaluation can provide valuable insights into the presence of liposarcoma.
- Medical History Assessment: A thorough evaluation of the patient’s medical history helps identify any risk factors or previous conditions that may contribute to the development of liposarcoma. This information assists in guiding further diagnostic procedures.
- Imaging Tests: a) X-Ray: X-rays are commonly used to evaluate bone abnormalities and to identify any calcified masses associated with liposarcoma. b) Computed Tomography (CT) Scan: CT scans create detailed cross-sectional images of the body, allowing doctors to visualize the size, location, and extent of the liposarcoma. c) Magnetic Resonance Imaging (MRI): MRIs utilize magnetic fields and radio waves to generate detailed images of soft tissues. This test helps determine the nature and extent of liposarcoma involvement. d) Positron Emission Tomography (PET) Scan: PET scans detect abnormal metabolic activity within the body, aiding in the identification of cancerous tissues and the detection of potential metastasis.
- Ultrasound: Ultrasound uses sound waves to create images of internal body structures. It can help visualize the tumor, assess its size, and guide a biopsy if necessary.
- Biopsy: A biopsy involves the removal of a tissue sample from the affected area for laboratory analysis. It helps confirm the diagnosis of liposarcoma and determines the specific subtype and grade.
- Fine Needle Aspiration (FNA) Biopsy: FNA biopsy involves inserting a thin needle into the tumor to extract a small sample of cells for examination. It is particularly useful in superficial liposarcomas or when obtaining tissue from deep-seated tumors is challenging.
- Core Needle Biopsy: Core needle biopsy uses a larger needle to obtain a core sample of tissue. This method provides a more extensive sample for analysis.
- Surgical Biopsy: In cases where the tumor is easily accessible, a surgical biopsy may be performed to remove a portion of or the entire tumor for further examination.
- Histopathological Analysis: Histopathology involves studying the tissue sample under a microscope to examine the cells’ characteristics and determine the presence of liposarcoma.
- Immunohistochemistry: Immunohistochemistry helps identify specific proteins expressed by liposarcoma cells, aiding in the differentiation of subtypes and guiding treatment decisions.
- Cytogenetic Analysis: Cytogenetic analysis examines the chromosomes of liposarcoma cells, detecting any genetic abnormalities or rearrangements. This analysis is particularly relevant for well-differentiated liposarcomas.
- Fluorescence In Situ Hybridization (FISH): FISH is a molecular genetic technique that detects specific DNA sequences and gene rearrangements in liposarcoma cells. It assists in confirming the diagnosis and identifying subtype-specific abnormalities.
- Molecular Testing: Molecular testing analyzes the genetic material of the tumor to identify specific gene mutations or alterations, providing valuable insights into prognosis and potential treatment options.
- Blood Tests: Blood tests assess general health parameters, liver function, and blood cell counts. They can help detect abnormalities associated with liposarcoma and assess overall patient fitness for treatment.
- Lymph Node Biopsy: In cases where metastasis is suspected, a biopsy of nearby lymph nodes may be performed to determine if cancer cells have spread beyond the original site.
- Bone Marrow Biopsy: If there is a suspicion of advanced disease or bone marrow involvement, a bone marrow biopsy may be performed to assess the extent of metastasis.
- Chest X-Ray: A chest X-ray can help identify potential lung metastases associated with liposarcoma.
- Chest CT Scan: A CT scan of the chest provides more detailed images of the lungs, helping detect and evaluate any suspected metastases.
- Abdominal Ultrasound: An abdominal ultrasound is used to assess the liver and other abdominal organs for signs of metastasis.
- Abdominal CT Scan: A CT scan of the abdomen provides detailed images of the abdominal organs, aiding in the identification of metastatic spread.
- Brain MRI: In cases where liposarcoma is suspected to have spread to the brain, an MRI of the brain may be performed to assess metastasis.
- Bone Scan: A bone scan helps identify bone metastases by detecting abnormal bone turnover and activity.
- PET-CT Scan: A combined PET-CT scan provides a comprehensive assessment of the entire body, aiding in the identification of primary and metastatic liposarcoma lesions.
- Genetic Counseling: Genetic counseling may be recommended for patients with a family history of liposarcoma or specific genetic syndromes associated with an increased risk.
- Second Opinion: Seeking a second opinion from a specialized oncologist can provide valuable insights, confirm the diagnosis, and explore additional treatment options.
- Molecular Profiling: Molecular profiling analyzes the genetic makeup of the tumor to identify potential targetable mutations, assisting in personalized treatment approaches.
- Liquid Biopsy: Liquid biopsy involves analyzing a patient’s blood sample for circulating tumor DNA or tumor-related biomarkers. It provides a minimally invasive method for monitoring disease progression and treatment response.
- Prognostic Scoring Systems: Certain scoring systems, such as the French Federation of Cancer Centers Sarcoma Group (FNCLCC) system, evaluate various factors to predict the prognosis and overall survival of liposarcoma patients.
- Staging: Staging involves assessing the extent of the disease and determining the tumor’s size, invasion, and metastasis. Staging helps guide treatment decisions and predicts patient outcomes.
- Consultation with a Sarcoma Specialist: Consulting with a sarcoma specialist ensures access to the most up-to-date expertise and treatment options for liposarcoma, leading to optimal patient care.
Treatment
While treatment for liposarcoma depends on various factors such as tumor size, location, and stage, there are several effective treatment options available and different treatments for liposarcoma, providing detailed explanations and insights to help patients and their loved ones make informed decisions.
- Surgery: Surgery is often the primary treatment for liposarcoma. It involves the removal of the tumor and surrounding tissues to achieve complete resection.
- Radiation Therapy: Radiation therapy utilizes high-energy X-rays or other types of radiation to destroy cancer cells and reduce the risk of recurrence.
- Chemotherapy: Chemotherapy involves the use of powerful drugs to kill cancer cells. It can be administered before surgery to shrink tumors or after surgery to target remaining cancer cells.
- Targeted Therapy: Targeted therapy specifically targets certain molecules or genes that are involved in the growth and progression of liposarcoma. It aims to disrupt the cancer cells’ ability to grow and divide.
- Immunotherapy: Immunotherapy stimulates the patient’s immune system to recognize and destroy cancer cells. It can be used to enhance the body’s natural defenses against liposarcoma.
- Cryotherapy: Cryotherapy involves freezing cancer cells to destroy them. It is typically used for small tumors or to treat recurrent liposarcoma.
- Radiofrequency Ablation (RFA): RFA uses heat generated by high-frequency electrical currents to destroy cancer cells. It is often utilized for small tumors or in cases where surgery is not feasible.
- Chemoradiotherapy: Chemoradiotherapy combines chemotherapy with radiation therapy to enhance treatment effectiveness. It is typically used for larger or more advanced liposarcomas.
- Brachytherapy: Brachytherapy involves placing radioactive sources near the tumor to deliver targeted radiation. It can be used as a primary treatment or in combination with surgery.
- Liposuction: Liposuction may be used in certain cases to remove smaller liposarcomas or to assist with the removal of residual tumors after surgery.
- Watchful Waiting: Watchful waiting involves monitoring the tumor’s growth and progression without immediate treatment. This approach may be suitable for small, slow-growing tumors.
- Adjuvant Therapy: Adjuvant therapy refers to treatments administered after surgery to target any remaining cancer cells and reduce the risk of recurrence.
- Palliative Care: Palliative care focuses on relieving symptoms and improving the quality of life for patients with advanced liposarcoma. It aims to provide physical, emotional, and spiritual support.
- Proton Therapy: Proton therapy uses protons, rather than X-rays, to deliver radiation to the tumor. It is a precise form of radiation therapy that minimizes damage to surrounding healthy tissues.
- Clinical Trials: Participation in clinical trials provides access to experimental treatments and therapies that are not yet widely available. It allows patients to contribute to advancing liposarcoma research.
- Limb-Sparing Surgery: Limb-sparing surgery aims to remove the tumor while preserving the functionality of the affected limb. It is often employed for liposarcomas located in the extremities.
- Lymph Node Dissection: Lymph node dissection involves the surgical removal of nearby lymph nodes to determine if the cancer has spread. It helps guide further treatment decisions.
- Resection Margin Evaluation: Resection margin evaluation assesses the extent of tumor removal during surgery. It ensures that an adequate margin of healthy tissue has been excised along with the tumor.
- Chemoinfusion: Chemoinfusion delivers chemotherapy drugs directly into the affected limb through a catheter, maximizing the concentration of drugs in the tumor area.
- Intensity-Modulated Radiation Therapy (IMRT): IMRT is a precise form of radiation therapy that delivers high doses of radiation to the tumor while minimizing exposure to healthy tissues.
- Stereotactic Body Radiation Therapy (SBRT): SBRT delivers highly targeted radiation doses to the tumor using advanced imaging techniques. It is typically used for small, well-defined liposarcomas.
- Tumor Ablation: Tumor ablation techniques, such as microwave ablation or laser ablation, use heat or cold to destroy cancer cells. They can be used for small tumors or as palliative treatment.
- Hedgehog Pathway Inhibitors: Hedgehog pathway inhibitors are a type of targeted therapy that block the abnormal signaling pathways involved in liposarcoma growth.
- mTOR Inhibitors: mTOR inhibitors interfere with a protein pathway involved in cell growth and division. They can be used as targeted therapy for specific subtypes of liposarcoma.
- PD-1/PD-L1 Inhibitors: PD-1/PD-L1 inhibitors are immunotherapy drugs that block specific proteins, allowing the patient’s immune system to recognize and attack liposarcoma cells.
- Tyrosine Kinase Inhibitors (TKIs): TKIs are targeted therapy drugs that interfere with specific enzymes involved in cancer cell growth. They can be used for certain subtypes of liposarcoma.
- Liposomal Chemotherapy: Liposomal chemotherapy delivers chemotherapy drugs in liposome vesicles, enhancing drug delivery to tumor cells while reducing toxicity to healthy tissues.
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs may be used as part of a multimodal treatment approach to help manage pain and inflammation associated with liposarcoma.
- Supportive Therapies: Supportive therapies, such as physical therapy, occupational therapy, and psychological counseling, play a vital role in improving the overall well-being of liposarcoma patients.
- Multidisciplinary Care: Multidisciplinary care involves a team of healthcare professionals working together to develop and implement a comprehensive treatment plan tailored to each patient’s unique needs.
Medications
Drugs used in the treatment of liposarcoma, their mechanisms of action, and potential side effects.
- Adriamycin (doxorubicin): Doxorubicin is a widely used chemotherapy drug that works by interfering with DNA replication and causing cell death. Common side effects include hair loss, nausea, and increased risk of infection.
- Ifosfamide: Ifosfamide is another chemotherapy drug that inhibits DNA synthesis in cancer cells. It is often used in combination with doxorubicin. Side effects may include nausea, vomiting, and damage to the kidneys.
- Gemcitabine: Gemcitabine is a nucleoside analog that disrupts DNA synthesis, leading to cell death. It is administered intravenously and may cause flu-like symptoms, fatigue, and lowered blood cell counts.
- Trabectedin: Trabectedin is derived from a marine organism and works by disrupting cancer cell growth and repair. Side effects may include nausea, fatigue, and liver toxicity.
- Eribulin: Eribulin is a microtubule inhibitor that prevents cell division and growth. It is commonly used when liposarcoma has spread. Side effects may include fatigue, hair loss, and neuropathy.
- Pazopanib: Pazopanib is a targeted therapy that inhibits the growth of new blood vessels, thereby restricting the tumor’s blood supply. It is taken orally and may cause diarrhea, high blood pressure, and fatigue.
- Trabectedin + Olaratumab: Combining trabectedin with olaratumab, a monoclonal antibody, has shown improved outcomes in certain cases of liposarcoma. Olaratumab blocks the PDGFR-alpha receptor, inhibiting tumor growth. Side effects may include nausea, fatigue, and musculoskeletal pain.
- Sunitinib: Sunitinib is a tyrosine kinase inhibitor that targets multiple pathways involved in tumor growth. Common side effects include fatigue, diarrhea, and skin discoloration.
- Regorafenib: Regorafenib is another multi-targeted kinase inhibitor that blocks several pathways associated with tumor growth. Side effects may include hand-foot syndrome, hypertension, and gastrointestinal disturbances.
- Axitinib: Axitinib inhibits the activity of vascular endothelial growth factor receptors, reducing the blood supply to the tumor. It may cause diarrhea, fatigue, and hypertension.
- Nintedanib: Nintedanib targets multiple signaling pathways involved in tumor growth, including those related to blood vessel formation. It is associated with side effects such as diarrhea, liver enzyme elevation, and hypertension.
- Liposomal Doxorubicin: Liposomal doxorubicin is a specialized formulation of doxorubicin that improves drug delivery to the tumor site while minimizing side effects. Side effects may include fever, chills, and fatigue.
- Ixabepilone: Ixabepilone is a microtubule-stabilizing agent that disrupts cell division in liposarcoma cells. Side effects may include fatigue, neuropathy, and low blood cell counts.
- Methotrexate: Methotrexate is an antimetabolite drug that interferes with DNA synthesis and cell proliferation. It is associated with side effects such as mouth sores, nausea, and liver toxicity.
- Cyclophosphamide: Cyclophosphamide is an alkylating agent that damages DNA in cancer cells, preventing their replication. Side effects may include nausea, hair loss, and increased risk of infection.
- Etoposide: Etoposide inhibits an enzyme involved in DNA replication, causing cell death. Side effects may include hair loss, nausea, and lowered blood cell counts.
- Lurbinectedin: Lurbinectedin is a selective inhibitor of oncogenic transcription factors involved in tumor growth. It may cause fatigue, nausea, and myelosuppression.
- Pembrolizumab: Pembrolizumab is an immune checkpoint inhibitor that enhances the body’s immune response against cancer cells. Side effects may include fatigue, rash, and immune-related adverse events.
- Durvalumab: Durvalumab is another immune checkpoint inhibitor that activates the immune system against liposarcoma cells. It is associated with side effects such as fatigue, cough, and pneumonitis.
- Olaratumab: Olaratumab, when used in combination with doxorubicin, has shown improved outcomes in certain cases of liposarcoma. Side effects may include nausea, fatigue, and musculoskeletal pain.
Conclusion:
When it comes to liposarcoma treatment, a personalized approach is crucial. The wide array of available treatment options, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, provide hope and improved outcomes for patients. By considering factors such as tumor characteristics, stage, and individual patient preferences, healthcare professionals can guide patients towards the most suitable treatment plan. Ongoing research and participation in clinical trials offer even more opportunities to advance liposarcoma treatment options, providing hope for a brighter future in the fight against this rare cancer.
References
Previous
Lipoma
Next
